

REQUEST FOR ACCESS TO AN ABANDONED APPLICATION UNDER 37 CFR 1.14

In re Application of


Application Number

Filed

08-332046 Nov 1, 1994

Paper No. 461

Bring completed form to:
File Information Unit
Crystal Plaza Three, Room 1001,
2021 South Clark Place
Arlington, VA
Telephone: (703) 305-2733



I hereby request access under 37 CFR 1.14(a)(1)(iv) to the application file record of the above-identified ABANDONED application, which is identified in, or to which a benefit is claimed, in the following document(s) shown in the attachment:

United States Patent Application Publication No. _____, page, _____ line _____

United States Patent Number 6545142, column _____, line, _____ of _____

WIPO Pub. No. _____, page _____, line _____

Related Information about Access to Pending Applications (37 CFR 1.14)

Direct access to pending applications is not available to the public but copies may be available and may be purchased from the Office of Public Records upon payment of the appropriate fee (37 CFR 1.19(b)), as follows:

For published applications that are still pending, a member of the public may obtain a copy of:

the file contents;

the pending application as originally filed; or
any document in the file of the pending application.

For unpublished applications that are still pending:

(1) If the benefit of the pending application is claimed under 35 U.S.C. 119(e), 120, 121, or 365 in another application that has: (a) issued as a U.S. patent, or (b) published as a statutory invention registration, a U.S. patent application publication, or an international patent application publication in accordance with PCT Article 21(2), a member of the public may obtain a copy of:

the file contents;

the pending application as originally filed; or
any document in the file of the pending application.

(2) If the application is incorporated by reference or otherwise identified in a U.S. patent, a statutory invention registration, a U.S. patent application publication, or an international patent application publication in accordance with PCT Article 21(2), a member of the public may obtain a copy of:

the pending application as originally filed.

B. RHODES

Signature

BILL RHODES

Typed or printed name

Registration Number, if applicable

703-413-3667

Telephone Number

8-22-05

Date

FOR PTO USE ONLY

Approved by: Bill Rhodes

Unit:

RECEIVED

AUG 22 2005

This collection of information is required by 37 CFR 1.14. The information is required to obtain or retain a benefit by the public which is provided by the USPTO in processing an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take approximately 11 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form under suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 223-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. BRING TO: File Information Unit, Crystal Plaza Three, Room 1001, 2021 South Clark Place, Arlington, VA.



US006545142B1

(12) **United States Patent**
Winter et al.

(10) **Patent No.:** US 6,545,142 B1
(45) **Date of Patent:** Apr. 8, 2003

(54) **SINGLE DOMAIN LIGANDS, RECEPTORS
COMPRISING SAID LIGANDS, METHODS
FOR THEIR PRODUCTION, AND USE OF
SAID LIGANDS AND RECEPTORS**

(75) Inventors: **Gregory Paul Winter, Cambridge
(GB); Elizabeth Sally Ward,
Cambridge (GB); Detlef Güssow,
Cambridge (GB)**

(73) Assignee: **Medical Research Council of the
United Kingdom, London (GB)**

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 0 days.

(21) Appl. No.: 09/722,364

(22) Filed: **Nov. 28, 2000**

Related U.S. Application Data

(60) Continuation of application No. 08/470,031, filed on Jun. 6,
1995, now Pat. No. 6,248,516, which is a division of
application No. 08/332,046, filed on Nov. 1, 1994, now
abandoned, which is a continuation of application No.
07/796,805, filed on Nov. 25, 1991, now abandoned, which
is a division of application No. 07/580,374, filed on Sep. 11,
1990, now abandoned.

(30) **Foreign Application Priority Data**

Nov. 11, 1988	(GB)	8826444
Mar. 16, 1989	(GB)	8906034
Apr. 22, 1989	(GB)	8909217
May 15, 1989	(GB)	8911047
Jun. 2, 1989	(GB)	8912652
Jun. 16, 1989	(GB)	8913900
Aug. 15, 1989	(GB)	8918543
Nov. 13, 1989	(GB)	PCT/GB89/013444

(51) Int. Cl.⁷

C07H 21/04

(52) U.S. Cl. **536/24.33; 536/23.53**

(58) Field of Search **536/24.33, 23.53**

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,356,270 A	10/1982	Itakura
4,642,334 A	2/1987	Moore et al.
4,656,134 A	4/1987	Ringold
4,683,195 A	7/1987	Mullis et al.
4,683,202 A	7/1987	Mullis
4,704,692 A	11/1987	Ladner
4,711,845 A	12/1987	Gelfand et al.
4,714,681 A	12/1987	Reading
4,800,159 A	1/1989	Mullis et al.
4,806,471 A	2/1989	Molin et al.
4,816,397 A	3/1989	Boss et al.
4,889,818 A	12/1989	Gelfand et al.
4,937,193 A	6/1990	Hinchliffe et al.

(List continued on next page.)

FOREIGN PATENT DOCUMENTS

CA	2016841	11/1990
CA	2019323	12/1990
EP	A 0 120 694	10/1984

EP	A 0 125 023	11/1984
EP	0 194 276 B1	9/1986
EP	A 0 200 362	12/1986
EP	0 201 184 B1	12/1986
EP	A 0 239 400	9/1987
WO	WP 86/01533	3/1986
WO	WO 87/02671	5/1987

(List continued on next page.)

OTHER PUBLICATIONS

Inbar et al., PNAS—USA, 69, 2659–2662, 1972.
Amit et al., Science, 233, 747–753, 1986.
Satow et al., J. Mol. Biol. 190, 593–604, 1986.
Colman et al., Nature, 326, 358–363, 1987.
Sheriff et al., PNAS—USA, 84, 8075–8079, 1987.
Padlin et al., PNAS—USA, 86, 5938–5942, 1989.
Skerra and Plückthun, Science, 240, 1038–1041, 1988.
Bird et al., Science, 242, 423–426, 1988.
Huston et al., PNAS—USA, 85, 5879–5833, 1988.
Porter et al., J. Cell. Physiology, 67, 51–64, 1966.
Jaton et al., Biochemistry, 7, 4185–4195, 1968.
Rockey, J., J. Exp. Med., 125, 249–275, 1967.
Stevenson, Biochem. J., 133, 827–836, 1973.
Edmundson et al., Biochemistry, 14, 3953–3961, 1975.
Rossman et al., Nature, 317, 145–153, 1985.
Saiki et al., Science, 230, 1350–1354, 1985.
Lerrick, et al., Biochem. Biophys. Res. Comm., 160, 1250–1265, 1989.
Orlandi et al., PNAS—USA, 86, 3833, 1989.
You and Fried, Nuc. Acids. Res. 17, 4895, 1989.
Fields and Song, Nature, 340, 245–246, 1989.
Baldwin and Schultz, Science, 245, 1104–1107, 1989.
Menard et al., Cancer Res., 43, 1295–1300, 1983.
Bosslet et al., Eur. J. Nuc. Med., 14, 523–528, 1988.
Bosslet et al., Cancer Immunol. Immunother., 23, 185–191, 1986.
Bremer et al., J. Biol. Chem., 259, 14773–14777, 1984.
Griffiths & Milstein, Hybridoma Technology in the Bio-sciences and Medicine, 103–115, 1985.
Jones et al., Nature, 321, 522–525, 1986.
Zoller & Smith, Nuc. Acids Res., 10, 6487–6500, 1982.
Carter et al., Nuc. Acids Res., 13, 4431–4443, 1985.
Sanger et al., PNAS—USA, 74, 5463–5467, 1977.
Yannisch-Perron et al., Gene, 33, 103–119, 1985.
Riechmann et al., Nature, 332, 323–327, 1988.

(List continued on next page.)

Primary Examiner—James Ketter

(74) **Attorney, Agent, or Firm—Nixon & Vanderhye P.C.**

(57) **ABSTRACT**

The present invention relates to single domain ligands derived from molecules in the immunoglobulin (Ig) superfamily, receptors comprising at least one such ligand, methods for cloning, amplifying and expressing DNA sequences encoding such ligands, preferably using the polymerase chain reaction, methods for the use of said DNA sequences in the production of Ig-type molecules and said ligands or receptors, and the use of said ligands or receptors in therapy, diagnosis or catalysis.

2 Claims, 23 Drawing Sheets